J Antimicrob Chemother. 1992 Apr;29 Suppl A:95-104. doi: 10.1093/jac/29.suppl_a.95.
In an open, randomized multiclinic trial, hospitalized patients with upper or complicated lower urinary tract infections requiring treatment with a parenteral antibiotic were randomized to receive 1 g doses of cefpirome (594 patients) or ceftazidime (303 patients) 12 hourly for at least five days. Cefpirome was considerably more active in vitro than ceftazidime against Gram-positive pathogens isolated from the urine samples. At the early follow-up, 2-15 days after treatment, clinical cure was achieved in 86% and 82% of the patients in the cefpirome and ceftazidime groups respectively. Elimination of the causative pathogen without recurrence or early reinfection was achieved in 87% of the patients in both groups. Drug related adverse events occurred in 8.9% of cefpirome treated patients and in 4.6% of those receiving ceftazidime. No specific type of adverse reaction accounted for this difference. Treatment was discontinued because of adverse events in 2.5% and 1.7% of the patients respectively. Cefpirome was found to be safe and at least as effective as ceftazidime for the treatment of urinary tract infections in hospitalized patients.
在一项开放性、随机多中心试验中，需要接受胃肠外抗生素治疗的上尿路感染或复杂性下尿路感染住院患者被随机分为两组，一组每12小时接受1克头孢匹罗治疗（594例患者），另一组每12小时接受头孢他啶治疗（303例患者），至少治疗五天。头孢匹罗在体外对从尿液样本中分离出的革兰氏阳性病原体的活性明显高于头孢他啶。在治疗后2至15天的早期随访中，头孢匹罗组和头孢他啶组分别有86%和82%的患者实现了临床治愈。两组中均有87%的患者清除了致病病原体，且无复发或早期再感染情况。接受头孢匹罗治疗的患者中有8.9%发生了与药物相关的不良事件，接受头孢他啶治疗的患者中有4.6%发生了此类事件。这种差异没有特定类型的不良反应可解释。分别有2.5%和1.7%的患者因不良事件而停药。结果发现，对于住院患者的尿路感染治疗，头孢匹罗是安全的，且疗效至少与头孢他啶相当。
